Key insights
- Agilent's launch of the Cytation 9 cell imaging multimode reader signals continued innovation and growth in the biotech and pharmaceutical sectors. Recent positive earnings revisions by analysts and the company trading below fair value suggest potential upside, indirectly supporting positive sentiment in the broader medical devices and life sciences industries.
SANTA CLARA, Calif. - Agilent Technologies Inc. (NYSE:A) announced Wednesday the launch of the BioTek Cytation 9 cell imaging multimode reader, combining multimode microplate reading and high-content cell imaging capabilities in a single platform.
The instrument features inverted fluorescence microscopy, upright imaging, and a multimode microplate reader module. According to the company’s press release statement, the Cytation 9 offers twice the imaging speed compared to previous models and supports workflows from basic research through high-content screening.
The product is designed for researchers conducting cell-based and biochemical assays in pharmaceutical and biotechnology laboratories. The system builds on Agilent’s Cytation portfolio, which was first introduced in 2013.
"For over a decade, Agilent’s Cytation imagers have been used to automate tedious manual microscopy work and complex image analysis tasks," said Xavier Amouretti, Vice President, BioTek and Seahorse Business Unit Leader at Agilent. "Cytation 9 is designed around the same principles, with a broader application range and twice the imaging speed."
The company stated the new system was developed based on feedback from existing Cytation users and is intended to support advanced cell-based models used in disease and drug discovery research.
Agilent reported revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. With a market cap of $32.2 billion and revenue growth of 8.14% over the last twelve months, the company maintains a strong gross profit margin of 52.3%. According to InvestingPro analysis, Agilent currently trades below its Fair Value, placing it among undervalued stocks in the sector. The platform reveals that 10 analysts have recently revised their earnings upwards, one of several key insights available in the comprehensive Pro Research Report. The company provides analytical and clinical laboratory technologies.
In other recent news, Agilent Technologies has launched a new business unit, Agilent Advanced Therapeutics, by combining its contract development and manufacturing operations in Canada and the United States. This integration includes BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado, offering a range of manufacturing services for pharmaceutical companies. Additionally, Agilent announced an agreement to acquire Biocare Medical for approximately $950 million in cash, with the transaction expected to close by the fiscal fourth quarter of 2026. This acquisition aims to enhance Agilent’s position in immunohistochemistry, a method used in cancer diagnostics. BofA Securities has reiterated a Neutral rating for Agilent, maintaining a $150 price target following the acquisition announcement.
Meanwhile, Crawford & Company has appointed W. Bruce Swain, Jr. as its permanent president and CEO. Swain had been serving as the interim president and CEO since January 1, 2026. In another development, Contractor Connection, a network owned by Crawford & Company, has partnered with Helixco to integrate real-time documentation technology into its commercial repair program. This partnership aims to enhance Contractor Connection’s commercial managed repair operations by capturing and validating time and materials documentation during projects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.